India: Covaxin and Covishield vaccines invoke 50% fewer antibodies against B.1.617 coronavirus variant

Scientists at the Indian National Institute of Virology (NIV), Pune, have found that both Covaxin and Covishield produce half as many antibodies against the B.1.617 variant of the novel coronavirus as against the ‘original’ B.1 variant....More...

Norway: “there is no other thing than the [AstraZeneca] coronavirus vaccine that can explain that we have received that immune response”

The experts have worked on the basis of a hypothesis that the AstraZeneca vaccines triggered an unexpected immune reaction in the sick health workers, who have triggered the system so that a combination of blood clots and low platelets has been obtained.… ...More...

Antibody resistance of coronavirus variants B.1.351 (SA) and B.1.1.7 (UK)

“Findings on B.1.351 [South Africa variant] are more worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely owing to an E484K mutation.… ...More...